Incyte (INCY) EBITDA Margin (2010 - 2026)
Incyte's (INCY) quarterly EBITDA Margin came in at 41.69% in Q2 2026, down 194.0% YoY from 44.35% in Q2 2025, and up 76.2% on a QoQ basis from 23.66% in Q1 2026.
Incyte (INCY) EBITDA Margin (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of EBITDA Margin data on file, last reported at 41.69% in Q2 2026.
- Quarterly EBITDA Margin fell 194.0% year-over-year to 41.69% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 30.56% (up 476.0% YoY) and the FY2025 annual result came in at 29.46%, up 2802.0% from the prior year.
- EBITDA Margin advanced to 41.69% in Q2 2026, from 23.66% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 43.63% in Q2 2025 to a low of 45.81% in Q2 2024.
- A 5-year average of 17.76% and a median of 19.89% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 6611 bps — and 2025, when it surged 8944 bps.
- Tracing INCY's EBITDA Margin over 5 years: stood at 7.56% in 2022, then soared by 144 bps to 18.48% in 2023, then surged by 38 bps to 25.58% in 2024, then declined by 13 bps to 22.29% in 2025, then surged by 87 bps to 41.69% in 2026.
- The last three EBITDA Margin figures came in at 41.69% (Q2 2026), 23.66% (Q1 2026), and 22.29% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 41.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.69% |
| Mar 31, 2026 | 23.66% |
| Dec 31, 2025 | 22.29% |
| Sep 30, 2025 | 32.47% |
| Jun 30, 2025 | 43.63% |
| Mar 31, 2025 | 19.49% |
| Dec 31, 2024 | 25.58% |
| Sep 30, 2024 | 12.84% |
| Jun 30, 2024 | -45.81% |
| Mar 31, 2024 | 10.43% |
| Dec 31, 2023 | 18.48% |
| Sep 30, 2023 | 23.36% |
| Jun 30, 2023 | 20.30% |
| Mar 31, 2023 | 3.06% |
| Dec 31, 2022 | 7.56% |
| Sep 30, 2022 | 16.81% |
| Jun 30, 2022 | 27.92% |
| Mar 31, 2022 | 15.89% |
| Dec 31, 2021 | 12.83% |
| Sep 30, 2021 | 28.96% |